• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Elicera Therapeutics

2.85 SEK

+10.27 %

Less than 1K followers

ELIC

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+10.27 %
-1.39 %
-46.33 %
-44.06 %
-44.06 %
-51.09 %
+2.45 %
-37.48 %
-52.91 %

Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses.

Read more
Market cap
189.86M SEK
Turnover
2.03M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
21.8
2026

Interim report Q2'26

27.11
2026

Interim report Q3'26

16.2
2027

Annual report '26

Press release02.07.2026, 07.27

BioStock: BioStock publish BioVal™ analysis of Elicera Therapeutics' ELC-301 programme

Elicera Therapeutics
Press release18.06.2026, 15.22

Elicera Therapeutics Receives Positive Feedback from Swedish MPA on Planned Clinical Study with ELC-401 in Grade IV Glioma

Elicera Therapeutics
Regulatory press release08.06.2026, 08.40

Elicera Therapeutics: Elicera's Nomination Committee Proposes Margareth Jorvid as New Chair of the Board

Elicera Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release03.06.2026, 17.01

Elicera Therapeutics: Elicera publishes annual report for 2025

Elicera Therapeutics
Regulatory press release01.06.2026, 17.46

Elicera Therapeutics: Elicera announces outcome of the rights issue

Elicera Therapeutics
Press release25.05.2026, 09.10

Elicera Therapeutics announces that the final reporting and final payment from the EIC Accelerator for the CARMA study have been approved

Elicera Therapeutics
Press release19.05.2026, 10.10

DNB Carnegie Access: Elicera Therapeutics - Extended company presentation and Q&A

Elicera Therapeutics
Press release13.05.2026, 15.57

Elicera Therapeutics' CSO takes temporary leave to undergo medical treatment - Di Yu appointed Acting CSO

Elicera Therapeutics
Regulatory press release11.05.2026, 14.16

Elicera Therapeutics: Elicera publishes information document regarding the rights issue

Elicera Therapeutics
Press release21.04.2026, 20.53

DNB Carnegie Access: Elicera Therapeutics: Withdrawing fair value following rights issue announcement - Correction

Elicera Therapeutics
Press release21.04.2026, 11.15

DNB Carnegie Access: Elicera Therapeutics: Withdrawing fair value following rights issue announcement

Elicera Therapeutics
Regulatory press release21.04.2026, 08.31

Elicera Therapeutics carries out a rights issue of approximately SEK 73 million

Elicera Therapeutics
Regulatory press release21.04.2026, 08.01

Elicera Therapeutics AB (publ) Interim Report 1 January - 31 March 2026

Elicera Therapeutics
Press release20.03.2026, 08.53

Elicera Therapeutics Announces Swedish Cancer Society's Senior Investigator Award to Chief Development Officer Di Yu

Elicera Therapeutics
Press release13.03.2026, 06.48

DNB Carnegie Access: Elicera Therapeutics: Focused on the future of immuno-oncology

Elicera Therapeutics
Press release11.03.2026, 10.53

Elicera Therapeutics receives Notice of Allowance for Japanease patent protecting the ELC-401 CAR T-cell candidate

Elicera Therapeutics
Press release10.03.2026, 09.41

Elicera Therapeutics' Chief Scientific Officer Magnus Essand named Cancer Researcher of the Year 2026 by the Swedish Cancer Society (Cancerfonden)

Elicera Therapeutics
Regulatory press release06.03.2026, 08.30

Elicera Therapeutics reports complete metabolic response (CMR) and well tolerated treatment in first two patients of cohort 3 in CARMA study, bringing total CMR to 6 out of 8 treated patients

Elicera Therapeutics
Press release27.02.2026, 08.30

Elicera Therapeutics provides update on preclinical CAR T-cell program ELC-401 for glioblastoma: preclinical development concluded and clinical trial planning underway

Elicera Therapeutics
Press release18.02.2026, 13.57

Elicera Therapeutics to present ipdated CARMA study data on March 6, 2026, at the 10th Zurich Immuno-Oncology Conference

Elicera Therapeutics